

## UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/018,981	12/18/2001	Hao Yuan	13774-002001	2606
26161	7590 02/27/2004		EXAMINER	
FISH & RIC 225 FRANKI	HARDSON PC		OH, SI	MON J
BOSTON, M			ART UNIT	PAPER NUMBER
,			1615	

DATE MAILED: 02/27/2004

Please find below and/or attached an Office communication concerning this application or proceeding.



## **Advisory Action**

Application No.	Applicant(s)	
10/018,981	YUAN, HAO	
Examiner	Art Unit	
Simon J. Oh	1615	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 09 February 2004 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a

final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.
PERIOD FOR REPLY [check either a) or b)]
a) The period for reply expiresmonths from the mailing date of the final rejection.
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).
1. A Notice of Appeal was filed on <u>30 September 2003</u> . Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.
2. The proposed amendment(s) will not be entered because:
(a) they raise new issues that would require further consideration and/or search (see NOTE below);
(b) ☐ they raise the issue of new matter (see Note below);
(c) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
<ul><li>(d)  they present additional claims without canceling a corresponding number of finally rejected claims.</li><li>NOTE:</li></ul>
3. Applicant's reply has overcome the following rejection(s):
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
5. The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because:
6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.
7.☑ For purposes of Appeal, the proposed amendment(s) a) will not be entered or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.
The status of the claim(s) is (or will be) as follows:
Claim(s) allowed:
Claim(s) objected to:
Claim(s) rejected: <u>16-19 and 21</u> .
Claim(s) withdrawn from consideration:
8. ☐ The drawing correction filed on is a) ☐ approved or b) ☐ disapproved by the Examiner.
9. Note the attached Information Disclosure Statement(s)( PTO-1449) Paper No(s).
10. ☑ Other: <u>See Continuation Sheet</u>

**Advisory Action** 

U.S. Patent and Trademark Office

PRIMARY EXAMINER **GROUP 1500** 

PRIMARY EXAMINER
GROUP 1500

CARLOS A. AZPÚRU

Continuation of 10. Other: As previously indicated, 17 and 18 may be allowable if they are re-written into an independent form. Contrary to the applicant's assertions, the examiner has not raised new grounds for rejection, but is merely maintaining the position taken in the final rejection of 01 April 2003. The examiner does not assert that ischemic necrosis of the femoral head is a disease substantially similar to osteoporosis or to poor hemorheological index. Rather, the examiner stands by the general disclosure of the Yuan reference that states that the administration of Cajanus cajan (L.) Millsp is useful for preventing microcirculation, promoting blood vessel regeneration, absorbing necrotic bone, and regenerating new bone. In light of this general disclosure, the examiner maintains the previously established position that one of ordinary skill in the art would have a reasonable expectation of success in utilizing the methods of the prior art in treating osteoporosis and in improving hemorheological index.